Endothelin-1 (ET-1) induces resistance to bortezomib in human multiple myeloma cells via a pathway involving the ETB receptor and upregulation of proteasomal activity
Συγγραφέας
Vaiou M., Pangou E., Liakos P., Sakellaridis N., Vassilopoulos G., Dimas K., Papandreou C.Ημερομηνία
2016Γλώσσα
en
Λέξη-κλειδί
Επιτομή
Purpose: Bortezomib (BTZ) is used for the treatment of multiple myeloma (MM). However, a significant proportion of patients may be refractory to the drug. This study aimed to investigate whether the endothelin (ET-1) axis may act as an escape mechanism to treatment with bortezomib in MM cells. Methods: NCI-H929 and RPMI-8226 (human MM cell lines) were cultured with or without ET-1, BTZ, and inhibitors of the endothelin receptors. ET-1 levels were determined by ELISA, while the protein levels of its receptors and of the PI3K and MAPK pathways’ components by western blot. Effects of ET-1 on cell proliferation were studied by MTT and on the ubiquitin proteasome pathway by assessing the chymotryptic activity of the 20S proteasome in cell lysates. Results: Endothelin receptors A and B (ETAR and ETBR, respectively) were found to be expressed in both cell lines, with the RPMI-8226 cells that are considered resistant to BTZ, expressing higher levels of ETBR and in addition secreting ET-1. Treatment of the NCI-H929 cells with ET-1 increased proliferation, while co-incubation of these cells with ET-1 and BTZ decreased BTZ efficacy with concomitant upregulation of 20S proteasomal activity. Si-RNA silencing or chemical blockade of ETBR abrogated the protective effects of ET-1. Finally, data suggest that the predominant signaling pathway involved in ET-1/ETBR-induced BTZ resistance in MM cells may be the MAPK pathway. Conclusion: Our data suggest a possible role of the ET-1/ETBR axis in regulating the sensitivity of MM cells to BTZ. Thus, combining bortezomib with strategies to target the ET-1 axis could prove to be a novel promising therapeutic approach in MM. © 2016, Springer-Verlag Berlin Heidelberg.
Collections
Related items
Showing items related by title, author, creator and subject.
-
Systemic therapy of metastatic bladder cancer in the molecular era: current status and future promise
Zachos, I.; Konstantinopoulos, P. A.; Tzortzis, V.; Gravas, S.; Karatzas, A.; Karamouzis, M. V.; Melekos, M.; Papavassiliou, A. G. (2010)Importance of the field: Platinum-based chemotherapy is considered the standard-of-care first-line therapy for metastatic bladder cancer. Despite the initial high response rate, the vast majority of patients eventually ... -
In vitro responsiveness of human post-menopausal myometrium to endothelin-1 and ovarian steroids
Domali, E.; Molyvdas, P. A.; Messinis, I. E. (2005)It has been shown in vitro that endothelin 1 (ET1) differentially affects the human myometrial contractility according to the hormonal profile of women. Our purpose was to test the hypothesis that ovarian steroids influence ... -
Systemic sclerosis: From pathogenesis towards targeted immunotherapies
Sakkas, L. I.; Chikanza, I. C.; Platsoucas, C. D. (2012)Systemic sclerosis (SSc), a chronic disease with widespread collagen deposition, has three pathogenetic facets: immune activation, microvasculopathy and fibroblast activation. Immune activation and microvasculopathy occur ...